Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imlygic extension study in melanoma
NCT01368276Phase 3Completed
- Sponsor
- BioVex Group, Inc.
- Start
- Oct 2010
- Primary completion
- Sep 2014
- Countries
- 2
01
Overview
A Phase 3 trial of talimogene laherparepvec in melanoma, sponsored by BioVex Group, Inc.. Started Oct 2010; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01368276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01368276.